XNASOABIW
Market cap386mUSD
Jan 10, Last price
0.45USD
1D
39.63%
1Q
35.61%
IPO
-18.64%
Name
Avista Public Acquisition Corp II
Chart & Performance
P/E
—
P/S
1.59
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
34m
-42.17%
Net income
-51m
L+126.65%
CFO
2m
P
Earnings
Mar 18, 2025
Profile
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 34,164 -42.17% | 59,077 70.02% | |||
Cost of revenue | 89,838 | 89,517 | |||
Unusual Expense (Income) | |||||
NOPBT | (55,674) | (30,440) | |||
NOPBT Margin | |||||
Operating Taxes | (13,744) | (3,727) | |||
Tax Rate | |||||
NOPAT | (41,930) | (26,713) | |||
Net income | (50,619) 126.65% | (22,334) -17.41% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (592) | 96,488 | |||
BB yield | 0.10% | -31.41% | |||
| Debt | |||||
Debt current | 6,972 | 1,780 | |||
Long-term debt | 47,636 | 49,812 | |||
Deferred revenue | 862 | 4,325 | |||
Other long-term liabilities | 3,233 | 4,135 | |||
Net debt | (32,375) | (37,122) | |||
| Cash flow | |||||
Cash from operating activities | 2,347 | (3,587) | |||
CAPEX | (1,644) | (17,168) | |||
Cash from investing activities | (18,376) | (73,313) | |||
Cash from financing activities | (892) | 110,739 | |||
FCF | (26,158) | (44,096) | |||
| Balance | |||||
Cash | 86,983 | 88,265 | |||
Long term investments | 449 | ||||
Excess cash | 85,275 | 85,760 | |||
Stockholders' equity | (39,305) | 11,273 | |||
Invested Capital | 387,032 | 360,871 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 99,683 | 85,318 | |||
Price | 6.17 71.39% | 3.60 -64.00% | |||
Market cap | 615,044 100.25% | 307,145 -62.82% | |||
EV | 582,669 | 270,023 | |||
EBITDA | (36,177) | (12,191) | |||
EV/EBITDA | |||||
Interest | 587 | ||||
Interest/NOPBT | |||||